DIAGENS-B

Hangzhou Diagens Biotech surged in the morning session, with a single-day gain of 5.36% to close at HK$444.4 from the previous close of HK$421.8, hitting an intraday high of HK$444.4 and low of HK$421.8. The rally follows recent news of the company's business scope expansion into AI and data services, which has attracted retail interest; previous reports noted a 27% surge. While operating revenue grew ~28% YoY, net losses widened sharply, with EPS at -HK$0.38 and ROE at -14.4%, underscoring ongoing profitability challenges. The stock trades 9.12% below its 52-week high of HK$489, but has gained 112% YTD and sits well above both its 20-day (HK$362.4) and 60-day (HK$342.3) moving averages, suggesting stretched valuation. However, recent trading has been volatile, with prior single-day drops exceeding 16%, reflecting divergent market views.

Hangzhou Diagens staged a sharp rally in the morning session, opening at HKD 331.4 and hitting an intraday high of HKD 396.2 before closing at HKD 391.6, up approximately 18.2%, driven by the launch of its iMedLoop medical AI platform and shareholder approval to expand business scope into AI and data services. The company's FY26 H1 revenue grew about 21% YoY to HKD 108.7 million, but net loss widened to HKD 55.88 million with a net margin of -51.4% and EPS of -0.3795, representing a YoY deterioration of ~4,000%. The stock trades at a PE of -248.44 and PB of 39.0, with a market cap of HKD 34.8 billion. While today's move reflects renewed AI optimism, the stock had previously experienced multiple sharp declines due to shifting AI valuation winds, and the fundamental loss expansion remains a headwind despite the price rebound.

2526.HK opened lower and dropped 5.2% to HK$346 in the morning session, as the company's FY26 H1 net loss widened to RMB55.88 million with deteriorating EPS, raising doubts about valuation recovery. The stock has retreated 29.2% from its 52-week high of HK$489 yet remains 94.4% above the 52-week low of HK$178, with YTD gains of 65.1%. The current price sits slightly below the 20-day MA of HK$347.4 but above the 60-day MA of HK$340.7, indicating weakening short-term support. Revenue grew about 28% YoY to RMB108.7 million, but net margin plunged to -51.4%, with losses far outpacing revenue growth. Though shareholders recently approved expanding the business scope into AI and data services, the earlier AI-driven rally is now facing profit-taking pressure amid earnings headwinds.

Hangzhou Diagens tumbled 5.1% to HK$357.2 by 11:11 BJ, from prior close of HK$376.6, with thin volume of 1,200 shares and turnover of HK$446,310. The company's FY26 H1 loss widened to RMB 55.88 million despite a 21% revenue rise to RMB 108.69 million, as net profit margin stood at -51.4% and EPS of -HK$0.3795 surged nearly 40x YoY, severely denting sentiment. The stock is 27% below its 52-week high of HK$489, yet trades above its MA20 (HK$343.54) and MA60 (HK$340.63), with YTD gain of 70.4%. Recent moves to expand into AI and data services were approved by 77.78% of votes at an EGM, but mounting losses and a high PB of 35.58x contrast with the AI narrative, while low liquidity points to lingering uncertainty.

Diagens-B opened high and drifted lower in the morning session, falling 6.68% from HK$374 to HK$349 with minimal turnover of only HK$92,250. The company recently reported a wider H1 FY2026 net loss of RMB55.88 million, despite a 21% revenue increase to RMB108.69 million, as EPS losses expanded nearly 40x YoY. Valuation metrics show a PB of 34.76x and negative PE. The current price of HK$349 is 28.63% below the 52-week high of HK$489 but still 66.51% above the YTD start, and sits above both the 20-day MA (HK$334.71) and 60-day MA (HK$338.15), indicating a resilient medium-term trend despite the day's pullback.